Antiplatelet therapy in peripheral arterial disease. Consensus statement

European Journal of Vascular and Endovascular Surgery

Volumn 26, Issue 1, 2003, Pages 1-16

  Stansby, G ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Angioplasty; Antiplatelet therapy; Consensus; Peripheral arterial disease; Vascular surgery

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPYRIDAMOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PICOTAMIDE; PLACEBO; ROFECOXIB; TICLOPIDINE;

ANGIOPLASTY; AORTA ANEURYSM; ARTERY BYPASS; ARTERY SURGERY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GRAFT OCCLUSION; HEADACHE; HEART INFARCTION; HUMAN; INFORMATION PROCESSING; INTERMITTENT CLAUDICATION; KIDNEY DISEASE; LIMB ISCHEMIA; MEDICAL DOCUMENTATION; MEDICAL SPECIALIST; PATIENT CARE; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; STENT; STROKE; VASCULAR DISEASE;

EID: 0037482963     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1927     Document Type: Article

References (93)

1. Leng G, Fowkes F, Lee A, Dunbar J, Housley E, Ruckley C. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313: 1440-1444.
2. Fowkes FGR, Housley E, Cawood EH, MacIntyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392.
3. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1982; 211: 249-256.
4. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg 1999; 12: 123-137.
5. Dormandy J, Murray G. The fate of the claudicant - a prospective study of 1969 claudicants. Eur J Vasc Surg 1991; 5: 131-133.
6. Newman A, Tyrrel K, Kuller L. Mortality over 4 years in SHEP participants with a low ankle arm index. J Am Geriatr Soc 1997; 45: 1472-1478.
7. Simonski E, Guralnik J, Hennekins C, Wallace R, Ostfeld A. Intermittent claudication and subsequent cardiovascular disease in the elderly. J Gerontol 1995; 50A: M17-M22.
8. Bainton D, Sweetnam P, Baker I, Elwood P. Br Heart J 1994; 72: 128-132.
9. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88: 787-800.
10. Hirsh J, Dalen J, Guyatt G. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest 2001; 119: 1S-2S.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patient. BMJ 1994; 308: 81-106.
12. Murphy MK, Black NA, Lamping DL et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998; 2: 1-88.
13. Michaels J, Booth A. Pragmatic System for the Grading of Evidence and Recommendations in Clincal Guidelines. J Clin Excellence 2001; 3: 139-143.
14. Kornitzer M, Dramaix M, Sobolski J, Degre S, De Backer G. Ankle/arm pressure index in asymptomatic middle-aged males: an independent predictor of ten-year coronary heart disease mortality. Angiology 1995; 46: 211-219.
15. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465-469.
16. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol 1994; 74: 64-65.
17. Howell MA, Colgan MP, Seeger RW, Ramsey DE, Sumner DS. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg 1989; 9: 691-696; discussion 696-697.
18. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen K, Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J (Clin Res Ed) 1986; 293: 1137-1140.
19. Hess H, Keil-Kuri E. Theoretische grundlagen der prophhylaxe obliterinerender arteriopathein mit aggregationshemmern undergebnisse einer langzeitstudie mit ASS (Colfarit). Proceedings of Colfarit symposium III. Koln, 1975: 80-87.
20. Colwell JA, Bingham SF. VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis. Haemostasis 1986; 16: 433-438.
21. Colwell JA, Bingham SF, Abraira C et al. Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care 1986; 9: 140-148.
22. Colwell JA, Bingham SF, Abraira C et al. VA Cooperative Study of antiplatelet agents in diabetic patients after amputation for gangrene: unobserved, sudden, and unexpected deaths. J Diabet Complications 1989; 3: 191-197.
23. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; 1: 415-419.
24. Arcan J, Blanchard J, Boissel J, Destors J, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988; 39: 802-811.
25. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med 1997; 337: 1726-1731.
26. Blanchard J, Carreras LO, Kindermans M. Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev Fr Hematol 1994; 35: 523-528.
27. Ellis D. Treatment of intermittent claudication with ticlopidine. Proceedings of International Committee on Thrombosis and Haemostasis, 32nd meeting, 1986, Jerusalem.
28. Janzon L, Bergqvist D, Boberg J et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301-308.
29. Krause D. Double blind study - Ticlopidine vs Placebo - in intermittent claudication. Sanofi internal report. Guilford: Sanofi Winthrop, 1983.
30. Shaw K. Assessment of the Effect of Ticlopidine on Diabetic Pre-Gangrene. Sanofi internal report 001.6.241. Guilford: Sanofi Winthrop, 1983.
31. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 1993; 87: 1563-1569.
32. Wood D, Durrington P, Poulter N. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80: S1-S29.
33. Department of Health. Preventing coronary heart disease in high risk patients. National Service Framework - Coronary Heart Diasese 2001; Chapter 2.0.
34. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
35. Beebe H, Dawson D, Cutler B et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041-2050.
36. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 Nov 16; 348: 1329-1339.
37. Libretti A, Catalano M. Treatment of claudication with dipyridamole and aspirin. Int J Clin Pharmacol Res 1986; 6: 59-60.
38. Schoop W, Levy H. Prevention of arterial occlusive disease with antiaggregants. Thromb Haemost 1983; 50: 137 (Abstract 416).
39. Schoop W. Late results of conservative therapy of arterial occlusive disease with antiaggregants. Internist 1984; 25: 429-433.
40. Schoop W. Open randomised study comparing ticlopidine with acetylsalicylic acid in the prevention of contralateral thrombosis in patients initially presenting with unilateral thrombosis. Guildford: Sanofi Winthrop, 1983: (internal report 001.6.174).
41. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psych 1991; 54: 1044-1054.
42. The Dutch Tia Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-1266.
43. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85: 265-271.
44. The CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS INVESTIGATORS. Effects of clopidogrel in addition to aspirin in patents with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
45. Diener Hc, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
46. Axisa B, Fishwick G, Bolia A et al. Complications following peripheral angioplasty. Ann R Coll Surg Engl 2002; 84: 39-42.
47. Taylor L, Jr, Porter J. Clinical and anatomical considerations for surgery in femoropopliteal disease and the result of surgery. Circulation 1991; 83: I63-I69.
48. Watson H, Belcher G, Horrocks M. Adjuvant medical therapy in peripheral bypass surgery. Br J Surg 1999; 86: 981-991.
49. Popma J, Ohman E, Weitz J, Lincoff A, Harrington R, Berger P. Antithrombotic therapy in Patients Undergoing Percutaneous Coronary Intervention. Chest 2001; 119: S321-S336.
50. Schwartz L, Bourassa MG, Lesperance J et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-1719.
51. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-168.
52. Matsumoto Y, Tani T, Watanabe K, Kimura Y. Effects of cilostazol, an antiplatelet drug, on smooth muscle cell proliferation after endothelial denudation in rats. Jpn J Pharmacol 1992; 58: 284.
53. Kubota Y, Kichikawa K, Uchida H et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol 1995; 30: 532-537.
54. Kunishima T, Musha H, Eto F et al. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 1997; 19: 1058-1066.
55. Tsuchikane E, Fukuhara A, Kobayashi T. Impact of Cilostazol on restenois after Percutaneous Coronary Balloon Angioplasty. Circulation 1999; 100: 21-26.
56. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
57. Tangelder M, Lawson J, Algra A, Eikelboom B. Systematic review of randomised controlled trials of aspirin and oral anti-coagulants in the prevention of graft occlusion and ischaemic events after infrainguinal bypass surgery. J Vasc Surg 1999; 30: 701-709.
58. Girolami B, Bernardi E, Prins M et al. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral artertial disease: a Meta-analysis. Eur J Vasc Endovasc Surg 2000; 19: 370-380.
59. Green RM, Roedersheimer LR, Deweese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery 1982; 92: 1016-1026.
60. Goldman M, Mccollum C. A prospective randomised study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vasc Surg 1984; 18: 217-221.
61. Kohler TR, Kaufman JL, Kacoyanis G et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery 1984; 96: 462-466.
62. Donaldson D, Salter M, Kester R et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vasc Surg 1985; 19: 224-230.
63. Mccollum C, Alexander C, Kenchington G, Franks P, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg 1991; 13: 150-161.
64. Kretschmer G, Herbst F, Prager M et al. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992; 127: 1112-1115.
65. Arfvidsson B, Lundgren F, Drott C, Schersen T, Lundholm K. Influence on coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990; 159: 556-560.
66. Dutch-BOA. Efficacy of oral anticoagulants comared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-351.
67. Sarac T, Huber T, Back M et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998; 28: 446-457.
68. Dacey LJ, Munoz JJ, Johnson ER et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 2000; 70: 1986-1990.
69. Chapman T, Bowley D, Lambert A, Walker A, Ashley S, Wilkins D. Haemorrhage associated with cobined clopidogrel and aspirin therapy - Correspondence. Eur J Vasc Endovasc Surg 2001; 22: 478-479.
70. Etani H, Kimura K, Isaka Y, Kim B, Naka M, Kinoshita N et al. Platelet accumulation in abdominal aortic aneurysms and the effect of antiplatelet drugs: assessment by indium platelet scintigraphy. Kaku Igaku 1992; 29: 651-657.
71. Powell JT, Brady AR, Thompson SG, Fowkes FGR, Greenhalgh RM. Are we ignoring the importance of ankle pressures in patients with abdominal aortic aneurysm? Eur J Vasc Endovasc Surg 2001; 21: 65-69.
72. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
73. Smout J, Stansby G. Aspirin resistance. Br J Surg 2002; 89: 4-5.
74. Helgason C, Bolin K, Hoff J et al. Development of aspirin resistance in persons with previous ischaemic stroke. Stroke 1994; 25: 2331-2336.
75. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, YI Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
76. Hankey G, Sudlow C, Dunbabin D. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease. Stroke 2000; 31: 1779.
77. Appel GB. COX-2 inhibitors and the kidney. Clin Exp Rheumatol 2001; 19: S37-40.
78. Breyer MD, Hao C, QI Z. Cyclooxygenase-2 selective inhibitors and the kidney. Curr Opin Crit Care 2001; 7: 393-400.
79. Dalen JE. Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction. Arch Intern Med 2002; 162: 1091-1092.
80. Ray WA, Murray KT. Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents? Am Heart J 2002; 143: 381-382.
81. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118-123.
82. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099-1104.
83. Weil J, Langman MJ, Wainwright P et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27-31.
84. Reicin AS, Shapiro D, Sperling RS, Barr E, YU Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (Ibuprofen, Diclofenac, and Nabumetone). Am J Cardiol 2002; 89: 204-209.
85. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002; 89: 3-9.
86. Fitzgerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001; 19: S31-S36.
87. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, Celocoxib, Rofecoxib, Meloxicam, Etodolac for osteoarthritis and rheumatoid arthritis. London, U.K.: National Institute for Clinical Excellence (NICE): Page 4 section 1.5.
88. Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract: Indigestion and non-steroidal anti-inflammatory drugs. BMJ 2001; 323: 1236-1239.
89. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-2038.
90. Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
91. Henry D, Lim LL, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566.
92. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
93. Fork FT, Lafolie P, Toth E, Lindgarde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol 2000; 35: 464-469.